Loading stockRelated stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockRelated stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
In this Annual Report, unless the context requires otherwise, references to the Company, Alzamend, we, our company and us refer to Alzamend Neuro, Inc., a Delaware corporation and its subsidiary. Company Overview We are a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer s disease ( Alzheimer s ), bipolar disorder ( BD ), major depressi…
$1.89
+$0.05 (+2.72%)
EOD Sep 18, 2026
ROIC dropped from -166.43% to -294.63%, capital efficiency is deteriorating.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$9M
▼ -94.3% YoY
Op. Margin
—
ROIC
-123.78%
▼ -128.2pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
-$7M
▼ -22.8% YoY
Net Debt
-$8M
Net Cash Position
Cash & Equiv.
$8M
Continue Research
SourceComputed from the 10-Q filed 10 Sept 2026, covering the period ending 31 Jul 2026, as reported to the SEC. Data last refreshed 11 Sept 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Apr. Sector medians are approximate S&P 500 benchmarks and update periodically.